# Cannabidiol lymphatic transport after oral administration assessed using a novel thoracic lymph duct cannulated conscious pig model

**Authors:** Vitalii Rizov, Peter Lukáč, Mikuláš Mlček, Petr Kozlík, Tomáš Křížek, Petr Jelínek, Petr Šodek, Michaela Sklenárová, Viktória Paulusová, Olesia Symkanych, Daniel Stránský, Anežka Klouček, Miroslav Šoóš, Martin Šíma, Tomáš Grus, Ondřej Slanař, Pavel Ryšánek

PMC · DOI: 10.1080/10717544.2025.2608913 · 2025-12-29

## TL;DR

This study uses a new pig model to assess how cannabidiol travels through the lymphatic system after being taken orally, showing differences compared to rat models.

## Contribution

A novel conscious pig model with thoracic lymph duct cannulation is developed for studying lymphatic transport of CBD.

## Key findings

- CBD oral bioavailability was higher for nanoemulsion compared to oil-based solution in pigs.
- Lymphatic transport of CBD was significantly lower in pigs than in rats for the oil solution but similar for nanoemulsion.
- The study highlights the importance of using higher species models for more human-relevant lymphatic transport assessments.

## Abstract

Lymphatic transport of drugs after oral administration is an important physiological process in highly lipophilic compounds, such as cannabidiol (CBD). The majority of lymphatic transport studies have been historically conducted in anesthetized rats. However, this animal model differs significantly from the humans regarding both anatomical and physiological features. The aim of this study was therefore to develop a novel animal model using pigs and to provide an interspecies comparison for the lymphatic transport of CBD. The thoracic lymph duct was cannulated via thoracotomy in three pigs and lymph and blood were sampled from conscious animals to assess the lymphatic transport parameters and basic pharmacokinetic parameters of CBD administered in two distinct drug formulations (sesame oil-based solution and nanoemulsion) using a two-period cross-over study design. The mean ± SD oral bioavailability (F) was 6.1 ± 0.9% for the oil solution and 9.2 ± 6.6% for the nanoemulsion. The relative bioavailability via lymph (FRL), i.e. the percentage of the systemically available drug that has been transported through the mesenteric lymph, was 20 ± 10% and 11 ± 13%, respectively. Whereas the FRL for the oil solution was 2.3-fold lower in pigs compared to rats, the FRL for the nanoemulsion was almost identical for both species. In conclusion, the lymphatic transport of CBD plays an important role after its oral administration. The particular parameters differed significantly between the rodent and higher non-rodent species. The use of higher species models is therefore warranted for the lymphatic transport assessment in settings close to humans.

## Linked entities

- **Chemicals:** cannabidiol (PubChem CID 644019)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Chemicals:** sesame oil (MESH:D012715), CBD (MESH:D002185)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Sus scrofa (pig, species) [taxon 9823], Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12777811/full.md

---
Source: https://tomesphere.com/paper/PMC12777811